FIGURE 4. Pattern of somatic mutations, MGMT DNA methylation and MMR gene mutations in treated glioblastomas.
From the following article:
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network
Nature 455, 1061-1068(23 October 2008)
doi:10.1038/nature07385
a, The mean number of validated somatic nucleotide substitutions per tumour for key sample groups is indicated on the y axis and denoted by the height of the bar histograms. Samples are grouped along the x axis according to treatment status of the patient (minus indicates untreated; plus indicates treated), DNA methylation status of MGMT (Meth, DNA methylated; minus, not methylated), and genetic status of MMR genes (minus, no genes mutated; Mut, one or more of the MLH1, MSH2, MSH6, or PMS2 genes mutated); the number below each bar indicates the number of samples in the group. Bars are colour-coded for types of nucleotide substitutions including G-to-A transitions at non-CpG sites (blue), G-to-A transitions at CpG sites (green), and other mutation types (grey). b, Bar histogram for mutation spectrum in the MMR genes as a function of treatment status and methylation status of MGMT. The colour code for substitution types is the same as in a.
Download file
If the slide opens in your browser, select "File > Save As" to save it.
Download Power Point slide (512K)Slides may be downloaded for educational use, according to the terms described in Nature Publishing Group's licensing policy.
BACK TO ARTICLE